Universal-Beteiligungs- und Servicegesellschaft’s Viridian Therapeutics VRDN Stock Holding History

Universal-Beteiligungs- und Servicegesellschaft’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-48,822	Closed	-$955K	–	2206
2026 Q1	$955K	Buy	48,822 +9,968	+26%	+$296K	﹤0.01%	1532
2025 Q4	$1.21M	Buy	+38,854	New	+$1.07M	﹤0.01%	1431

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft's VRDN Position: Q2 2026 in Review

Universal-Beteiligungs- und Servicegesellschaft sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 48,822 shares — an estimated $955K sold.

Universal-Beteiligungs- und Servicegesellschaft first reported a position in VRDN in Q4 2025 and held it in 2 quarters. The position peaked at $1.21M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Universal-Beteiligungs- und Servicegesellschaft reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
Universal-Beteiligungs- und Servicegesellschaft sold 48,822 Viridian Therapeutics shares in Q2 2026, an estimated $955K.
Universal-Beteiligungs- und Servicegesellschaft first reported a position in Viridian Therapeutics in Q4 2025 and held it in 2 quarters.
Universal-Beteiligungs- und Servicegesellschaft's Viridian Therapeutics position peaked at $1.21M in Q4 2025.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Universal-Beteiligungs- und Servicegesellschaft's 13F filing for Q2 2026, filed 6 Aug 2026.